Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0X3FX
|
|||
| Former ID |
DAP000097
|
|||
| Drug Name |
Naloxone
|
|||
| Synonyms |
Nalone; Nalossone; Naloxona; Naloxonum; Narcan; Narcanti; Narcon; DBL Naloxone; Nalossone [DCIT]; Naloxone HCl; EN 1530base; DBL Naloxone (TN); L-Naloxone; N-Allylnoroxymorphone; Nalone (TN); Naloxona [INN-Spanish]; Naloxone (INN); Naloxone [INN:BAN]; Naloxonum [INN-Latin]; Narcan (TN); Narcanti (TN); N-Allyl-noroxymorphone; L-N-Allyl-14-hydroxynordihydromorphinone; L-N-Allyl-7,8-dihydro-14-hydroxynormorphinone; N-Allyl-4,5alpha-epoxy-3,14-dihydroxy-6-morphinanon; Morphinan-6-one, 17-allyl-4,5alpha-epoxy-3,14-dihydroxy-(8CI); Morphinan-6-one, 4,5-epoxy-3,14-dihydroxy-17-(2-propenyl)-, (5alpha)-(9CI); (-)-N-allyl-14-hydroxynordihydroxymorphinan-6-one; (-)-Naloxone; (5alpha)-3,14-dihydroxy-17-prop-2-en-1-yl-4,5-epoxymorphinan-6-one; (5alpha)-4,5-Epoxy-3,14-dihydroxy-17-(2-propenyl)morphinan-6-one; 1-N-Allyl-14-hydroxynordihydromorphinone; 1-N-Allyl-7,8-dihydro-14-hydroxynormorphinone; 12-Allyl-7,7a,8,9-tetrahydro-3,7a-dihydroxy-4aH-8,9c-iminoethanophenanthro(4,5-bcd)furanone; 12-Allyl-7,7a,8,9-tetrahydro-3,7a-dihydroxy-4aH-8,9c-iminoethanophenanthro[4,5-bcd]furan-5(6H)-one; 17-Allyl-4,5-alpha-epoxy-3,14-dihydroxymorphinan-6-one; 17-Allyl-4,5alpha-epoxy-3,14-dihydroxymorphinan-6-one; 17-allyl-3,14-dihydroxy-4,5alpha-epoxymorphinan-6-one; 3,14-dihydroxy-17-(prop-2-en-1-yl)-4,5alpha-epoxymorphinan-6-one
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Narcotic depression [ICD-11: 6A7Z; ICD-10: F32.8, F32.9; ICD-9: 304.9, 311] | Approved | [1], [2] | |
| Pruritus [ICD-11: EC90; ICD-10: L29, L29.9; ICD-9: 698] | Phase 3 | [3], [4] | ||
| Respiratory depression [ICD-11: MD11.5; ICD-10: R06.0] | Phase 3 | [5] | ||
| Opioid dependence [ICD-11: 6C43.2Z] | Phase 1 | [5] | ||
| Therapeutic Class |
Antinarcotic Agents
|
|||
| Company |
Bristol Meyers Squibb
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C19H21NO4
|
|||
| Canonical SMILES |
C=CCN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)O)O4)O
|
|||
| InChI |
1S/C19H21NO4/c1-2-8-20-9-7-18-15-11-3-4-12(21)16(15)24-17(18)13(22)5-6-19(18,23)14(20)10-11/h2-4,14,17,21,23H,1,5-10H2/t14-,17+,18+,19-/m1/s1
|
|||
| InChIKey |
UZHSEJADLWPNLE-GRGSLBFTSA-N
|
|||
| CAS Number |
CAS 465-65-6
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| ChEBI ID |
CHEBI:7459
|
|||
| ADReCS Drug ID | BADD_D01525 ; BADD_D01526 | |||
| SuperDrug ATC ID |
V03AB15
|
|||
| SuperDrug CAS ID |
cas=000465656
|
|||
| Interaction between the Drug and Microbe | Top | |||
|---|---|---|---|---|
| The Metabolism of Drug Affected by Studied Microbe(s) | ||||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Bacteroidales | ||||
|
Studied Microbe: Bacteroides coprophilus DSM 18228
Show/Hide Hierarchy
|
[6] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Naloxone can be metabolized by Bacteroides coprophilus DSM 18228 (log2FC = -0.98; p = 0.02). | |||
|
Studied Microbe: Bacteroides fragilis ATCC43859
Show/Hide Hierarchy
|
[6] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Naloxone can be metabolized by Bacteroides fragilis ATCC43859 (log2FC = -5.155; p = 0.016). | |||
|
Studied Microbe: Bacteroides fragilis HMW 610
Show/Hide Hierarchy
|
[6] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Naloxone can be metabolized by Bacteroides fragilis HMW 610 (log2FC = -3.708; p = 0.0). | |||
|
Studied Microbe: Bacteroides fragilis str. 3397 T10
Show/Hide Hierarchy
|
[6] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Naloxone can be metabolized by Bacteroides fragilis str. 3397 T10 (log2FC = -0.924; p = 0.011). | |||
|
Studied Microbe: Bacteroides fragilis str. 3986 T(B)9
Show/Hide Hierarchy
|
[6] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Naloxone can be metabolized by Bacteroides fragilis str. 3986 T(B)9 (log2FC = -0.839; p = 0.018). | |||
|
Studied Microbe: Bacteroides fragilis str. DS-208
Show/Hide Hierarchy
|
[6] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Naloxone can be metabolized by Bacteroides fragilis str. DS-208 (log2FC = -0.898; p = 0.011). | |||
|
Studied Microbe: Bacteroides ovatus ATCC 8483
Show/Hide Hierarchy
|
[6] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Naloxone can be metabolized by Bacteroides ovatus ATCC 8483 (log2FC = -0.722; p = 0.009). | |||
|
Studied Microbe: Bacteroides thetaiotaomicron 3731
Show/Hide Hierarchy
|
[6] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Naloxone can be metabolized by Bacteroides thetaiotaomicron 3731 (log2FC = -0.548; p = 0.045). | |||
|
Studied Microbe: Bacteroides thetaiotaomicron 7330
Show/Hide Hierarchy
|
[6] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Naloxone can be metabolized by Bacteroides thetaiotaomicron 7330 (log2FC = -0.723; p = 0.009). | |||
|
Studied Microbe: Bacteroides thetaiotaomicron VPI-5482
Show/Hide Hierarchy
|
[6] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Naloxone can be metabolized by Bacteroides thetaiotaomicron VPI-5482 (log2FC = -0.663; p = 0.009). | |||
|
Studied Microbe: Bacteroides uniformis ATCC 8492
Show/Hide Hierarchy
|
[6] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Naloxone can be metabolized by Bacteroides uniformis ATCC 8492 (log2FC = -0.694; p = 0.005). | |||
|
Studied Microbe: Pretovella copri DSM 18205
Show/Hide Hierarchy
|
[6] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Naloxone can be metabolized by Pretovella copri DSM 18205 (log2FC = -0.366; p = 0.04). | |||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Opioid receptor mu (MOP) | Target Info | Antagonist | [7], [8] |
| KEGG Pathway | Neuroactive ligand-receptor interaction | |||
| Estrogen signaling pathway | ||||
| Morphine addiction | ||||
| NetPath Pathway | TCR Signaling Pathway | |||
| Panther Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||
| Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | ||||
| Enkephalin release | ||||
| Pathway Interaction Database | IL4-mediated signaling events | |||
| Reactome | Peptide ligand-binding receptors | |||
| G alpha (i) signalling events | ||||
| WikiPathways | TCR Signaling Pathway | |||
| GPCRs, Class A Rhodopsin-like | ||||
| Peptide GPCRs | ||||
| Opioid Signalling | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1668). | |||
| REF 2 | Opioid drug utilization and cost outcomes associated with the use of buprenorphine-naloxone in patients with a history of prescription opioid use. J Manag Care Pharm. 2008 Mar;14(2):186-94. | |||
| REF 3 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 4 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 5 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 6 | Mapping human microbiome drug metabolism by gut bacteria and their genes. Nature. 2019 Jun;570(7762):462-467. | |||
| REF 7 | OxyContin abuse and overdose. Postgrad Med. 2009 Mar;121(2):163-7. | |||
| REF 8 | Mu opioid receptor antagonists: recent developments. ChemMedChem. 2007 Nov;2(11):1552-70. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.